Detection of high frequency of mutations in a breast and/or ovarian cancer cohort: Implications of embracing a multi-gene panel in molecular diagnosis in India

Journal of Human Genetics

Volumn 61, Issue 6, 2016, Pages 515-522

  Mannan, Ashraf U ^a   Singh, Jaya ^a   Lakshmikeshava, Ravikiran ^a   Thota, Nishita ^a   Singh, Suhasini ^a   Sowmya, T S ^a   Mishra, Avshesh ^a   Sinha, Aditi ^a   Deshwal, Shivani ^a   Soni, Megha R ^a   Chandrasekar, Anbukayalvizhi ^a   Ramesh, Bhargavi ^a   Ramamurthy, Bharat ^a   Padhi, Shila ^a   Manek, Payal ^a   Ramalingam, Ravi ^a   Kapoor, Suman ^a   Ghosh, Mithua ^b   Sankaran, Satish ^a   Ghosh, Arunabha ^a   Veeramachaneni, Vamsi ^a   Ramamoorthy, Preveen ^a,c   Hariharan, Ramesh ^a,d   Subramanian, Kalyanasundaram ^a   more..

^a Strand Life Sciences ^*  (India)

^b Triesta Sciences   (India)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d INDIAN INSTITUTE OF SCIENCE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BREAST CANCER; COHORT ANALYSIS; COMPUTER PROGRAM; EARLY CANCER DIAGNOSIS; FAMILY; FEMALE; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIATION; GROUPS BY AGE; HUMAN; INDIA; MAJOR CLINICAL STUDY; MIDDLE AGED; MOLECULAR DIAGNOSIS; MULTIGENE FAMILY; NEXT GENERATION SEQUENCING; OVARY CANCER; SEQUENCE ANALYSIS; SEQUENTIAL ANALYSIS; TUMOR GENE; AGED; BREAST NEOPLASMS; COPY NUMBER VARIATION; GENE DELETION; GENE DUPLICATION; GENETIC SCREENING; GENETICS; HEREDITARY BREAST AND OVARIAN CANCER SYNDROME; HIGH THROUGHPUT SEQUENCING; MUTATION; MUTATION RATE; ONSET AGE; OVARIAN NEOPLASMS; PREVALENCE; PROCEDURES; TUMOR SUPPRESSOR GENE; YOUNG ADULT;

ADULT; AGE OF ONSET; AGED; BREAST NEOPLASMS; DNA COPY NUMBER VARIATIONS; FEMALE; GENE DELETION; GENE DUPLICATION; GENES, BRCA1; GENES, BRCA2; GENETIC TESTING; HEREDITARY BREAST AND OVARIAN CANCER SYNDROME; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; INDIA; MIDDLE AGED; MUTATION; MUTATION RATE; OVARIAN NEOPLASMS; PREVALENCE; YOUNG ADULT;

EID: 84976556872     PISSN: 14345161     EISSN: 1435232X     Source Type: Journal    
DOI: 10.1038/jhg.2016.4     Document Type: Article

References (43)

1. Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet-Tieulent, J. & Jemal, A. Global cancer statistics, 2012. CA Cancer J. Clin. 65, 87-108 (2015).
2. Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136, E359-E386 (2015).
3. Jemal, A., Center, M. M., DeSantis, C. & Ward, E. M. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol. Biomarkers Prev. 19, 1893-1907 (2010).
4. Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P. A., Harshman, K., Tavtigian, S. et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266, 66-71 (1994).
5. Wooster, R., Bignell, G., Lancaster, J., Swift, S., Seal, S., Mangion, J. et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 378, 789-792 (1995).
6. Meindl, A., Ditsch, N., Kast, K., Rhiem, K. & Schmutzler, R. K. Hereditary breast and ovarian cancer: new genes, new treatments, new concepts. Dtsch. Arztebl. Int. 108, 323-330 (2011).
7. Becker, K. F., Atkinson, M. J., Reich, U., Becker, I., Nekarda, H., Siewert, J. R. et al. E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res. 54, 3845-3852 (1994).
8. Liaw, D., Marsh, D. J., Li, J., Dahia, P. L., Wang, S. I., Zheng, Z. et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat. Genet. 16, 64-67 (1997).
9. Hemminki, A., Markie, D., Tomlinson, I., Avizienyte, E., Roth, S., Loukola, A. et al. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 391, 184-187 (1998).
10. Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H. et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250, 1233-1238 (1990).
11. Broeks, A., Urbanus, J. H., Floore, A. N., Dahler, E. C., Klijn, J. G., Rutgers, E. J. et al. ATM-heterozygous germline mutations contribute to breast cancer-susceptibility. Am. J. Hum. Genet. 66, 494-500 (2000).
12. Cantor, S. B., Bell, D. W., Ganesan, S., Kass, E. M., Drapkin, R., Grossman, S. et al. BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function. Cell 105, 149-160 (2001).
13. Meijers-Heijboer, H., van den Ouweland, A., Klijn, J., Wasielewski, M., de Snoo, A., Oldenburg, R. et al. Low-penetrance susceptibility to breast cancer due to CHEK2() 1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat. Genet. 31, 55-59 (2002).
14. Bogdanova, N., Feshchenko, S., Schürmann, P., Waltes, R., Wieland, B., Hillemanns, P. et al. Nijmegen Breakage Syndrome mutations and risk of breast cancer. Int. J. Cancer 122, 802-806 (2008).
15. Heikkinen, K., Rapakko, K., Karppinen, S.-M., Erkko, H., Knuutila, S., Lundán, T. et al. RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability. Carcinogenesis 27, 1593-1599 (2006).
16. Rahman, N., Seal, S., Thompson, D., Kelly, P., Renwick, A., Elliott, A. et al. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat. Genet. 39, 165-167 (2007).
17. Meindl, A., Hellebrand, H., Wiek, C., Erven, V., Wappenschmidt, B., Niederacher, D. et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat. Genet. 42, 410-414 (2010).
18. Rodríguez-López, R., Osorio, A., Ribas, G., Pollán, M., Sánchez-Pulido, L., de la Hoya, M. et al. The variant E233G of the RAD51D gene could be a low-penetrance allele in high-risk breast cancer families without BRCA1/2 mutations. Int. J. Cancer 110, 845-849 (2004).
19. Vaidyanathan, K., Lakhotia, S., Ravishankar, H. M., Tabassum, U., Mukherjee, G. & Somasundaram, K. BRCA1 and BRCA2 germline mutation analysis among Indian women from south India: Identification of four novel mutations and high-frequency occurrence of 185delAG mutation. J. Biosci. 34, 415-422 (2009).
20. Valarmathi, M. T., Sawhney, M., Deo, S. S. V, Shukla, N. K. & Das, S. N. Novel germline mutations in the BRCA1 and BRCA2 genes in Indian breast and breast-ovarian cancer families. Hum. Mutat. 23, 205 (2004).
21. Rajkumar, T., Soumittra, N., Nancy, N. K., Swaminathan, R., Sridevi, V. & Shanta, V. BRCA1, BRCA2 and CHEK2 (1100 del C) germline mutations in hereditary breast and ovarian cancer families in South India. Asian Pac. J. Cancer Prev. 4, 203-208 (2003).
22. Hansa, J., Kannan, R. & Ghosh, S. K. Screening of 185DelAG, 1014DelGT and 3889DelAG BRCA1 mutations in breast cancer patients from North-East India. Asian Pac. J. Cancer Prev. 13, 5871-5874 (2012).
23. Hedau, S., Jain, N., Husain, S. A, Mandal, A. K., Ray, G., Shahid, M. et al. Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India. Breast Cancer Res. Treat. 88, 177-186 (2004).
24. Kumar, B. V., Lakhotia, S., Ankathil, R., Madhavan, J., Jayaprakash, P. G., Nair, M. K. et al. Germline BRCA1 mutation analysis in Indian breast/ovarian cancer families. Cancer Biol. Ther. 1, 18-21 (2002).
25. Saxena, S., Chakraborty, A., Kaushal, M., Kotwal, S., Bhatanager, D., Mohil, R. S. et al. Contribution of germline BRCA1 and BRCA2 sequence alterations to breast cancer in Northern India. BMC Med. Genet. 7, 75 (2006).
26. Rajkumar, T., Meenakumari, B., Mani, S., Sridevi, V. & Sundersingh, S. Targeted Resequencing of 30 Genes Improves the Detection of Deleterious Mutations in South Indian Women with Breast and/or Ovarian Cancers. Asian Pac. J. Cancer Prev. 16, 5211-5217 (2015).
27. Richards, C. S., Bale, S., Bellissimo, D. B., Das, S., Grody, W. W., Hegde, M. R. et al. ACMG recommendations for standards for interpretation and reporting of sequence variations: Revisions 2007. Genet. Med. 10, 294-300 (2008).
28. Chan, K. C. A., Jiang, P., Chan, C. W. M., Sun, K., Wong, J., Hui, E. P. et al. Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing. Proc. Natl Acad. Sci. USA 110, 18761-18768 (2013).
29. Ihaka, R. & Gentleman, R. R: A language for data analysis and graphics. J. Comput. Graph. Stat. 5, 299-314 (1996).
30. Struewing, J. P., Abeliovich, D., Peretz, T., Avishai, N., Kaback, M. M., Collins, F. S. et al. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat. Genet. 11, 198-200 (1995).
31. Tung, N., Battelli, C., Allen, B., Kaldate, R., Bhatnagar, S., Bowles, K. et al. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel. Cancer 121, 25-33 (2015).
32. Lincoln, S. E., Kobayashi, Y., Anderson, M. J., Yang, S., Desmond, A. J., Mills, M. A. et al. A systematic comparison of traditional and multigene panel testing for hereditary breast and ovarian cancer genes in more than 1000 Patients. J. Mol. Diagn. 17, 533-544 (2015).
33. Castéra, L., Krieger, S., Rousselin, A., Legros, A., Baumann, J.-J., Bruet, O. et al. Nextgeneration sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes. Eur. J. Hum. Genet. 22, 1305-1313 (2014).
34. Minion, L. E., Dolinsky, J. S., Chase, D. M., Dunlop, C. L., Chao, E. C. & Monk, B. J. Hereditary predisposition to ovarian cancer, looking beyond BRCA1/BRCA2. Gynecol. Oncol. 137, 86-92 (2015).
35. Kurian, A. W., Hare, E. E., Mills, M. A., Kingham, K. E., McPherson, L., Whittemore, A. S. et al. Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. J. Clin. Oncol. 32, 2001-2009 (2014).
36. Desmond, A., Kurian, A. W., Gabree, M., Mills, M. A., Anderson, M. J., Kobayashi, Y. et al. Clinical actionability of multigene panel testing for hereditary breast and ovarian cancer risk assessment. JAMA Oncol. 02114, 1-9 (2015).
37. Kim, H. & Choi, D. H. Distribution of BRCA1 and BRCA2 mutations in asian patients with breast cancer. J. Breast Cancer 16, 357-365 (2013).
38. Karami, F. & Mehdipour, P. A comprehensive focus on global spectrum of BRCA1 and BRCA2 mutations in breast cancer. Biomed Res. Int. 2013, 928562 (2013).
39. Kadalmani, K., Deepa, S., Bagavathi, S., Anishetty, S., Thangaraj, K. & Gajalakshmi, P. Independent origin of 185delAG BRCA1 mutation in an Indian family. Neoplasma 54, 51-56 (2007).
40. Feng, Y., Chen, D., Wang, G.-L., Zhang, V. W. & Wong, L.-J. C. Improved molecular diagnosis by the detection of exonic deletions with target gene capture and deep sequencing. Genet. Med. 17, 99-107 (2015).
41. Saxena, S., Szabo, C. I., Chopin, S., Barjhoux, L., Sinilnikova, O., Lenoir, G. et al. BRCA1 and BRCA2 in Indian breast cancer patients. Hum. Mutat. 20, 473-474 (2002).
42. NCRP (National Cancer Registry Programme). Time Trends in Cancer Incidence Rates 1982-2010. (Indian Council of Medical Research, Bangalore, 2013).
43. Allemani, C., Weir, H. K., Carreira, H., Harewood, R., Spika, D., Wang, X.-S. et al. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet 385, 977-1010 (2014).